COTE1 Inhibitors
COTE1 inhibitors encompass a variety of chemical compounds that exert their influence by perturbing the signaling pathways essential for COTE1's functional activity. Rapamycin and its derivative, Everolimus, bind to FKBP12 to form a complex that inhibits the mTOR kinase, a pivotal regulator of cellular growth and proliferation that COTE1's activity is contingent upon. Similarly, LY 294002 and Wortmannin, as selective PI3K inhibitors, and PP242, alongside AZD8055, as mTOR ATP-competitive inhibitors, lead to the suppression of the PI3K/AKT/mTOR pathway, substantially reducing the downstream signaling responsible for COTE1's activity. These inhibitors, by curbing the activation of AKT (as achieved by Triciribine) and subsequently mTOR, create a cellular environment where COTE1 activity is decreased due to the lack of stimulatory signals that are normally propagated through this pathway.
Further refining this modulation, compounds like Palomid 529, which target both TORC1/TORC2, and KU 0063794, as well as PP242, which are advanced molecules inhibiting both mTORC1 and mTORC2, ensure a comprehensive dampening of the mTOR pathway intricately linked with COTE1 function. PF-04691502, by dually inhibiting PI3K and mTOR kinases, disrupts the signaling cascade at multiple junctures, leading to a pronounced decrease in COTE1 activity. These chemical inhibitors operate by creating a deficit in the cellular signaling milieu that COTE1 relies on, thereby ensuring that the protein's activity is diminished. The collective action of these inhibitors on different nodes of the mTOR pathway exemplifies a strategic blockade that effectively diminishes the functional activity of COTE1 without altering its expression levels, highlighting the critical role of mTOR signaling in governing COTE1's role in the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically binds to FKBP12 and the resulting complex inhibits mTOR (mechanistic target of rapamycin), a kinase involved in cell growth and proliferation. Since COTE1 is implicated in processes that are regulated by mTOR, the inhibition of mTOR would lead to diminished COTE1 activity as the cell's growth signals would be downregulated. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a selective inhibitor of PI3K (phosphoinositide 3-kinase). PI3K is part of the AKT/mTOR signaling pathway, which is crucial for regulating cell survival and growth. Inhibition of PI3K results in reduced activation of AKT, leading to decreased mTOR activity and subsequently lowering COTE1 activity due to the reliance of COTE1 on mTOR signaling for its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent and selective inhibitor of PI3K. By inhibiting PI3K, it disrupts the PI3K/AKT/mTOR pathway, which is necessary for numerous cellular functions. This disruption results in diminished COTE1 activity, as the signaling events that would normally enhance COTE1 function are inhibited. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically targets AKT, inhibiting its phosphorylation and activation. AKT is a central component of the PI3K/AKT/mTOR pathway, and its inhibition leads to reduced mTOR signaling, which in turn diminishes COTE1 activity due to its dependence on mTOR for functional activity. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is a derivative of rapamycin and acts similarly by binding to FKBP12, forming a complex that inhibits mTOR. As mTOR is a downstream effector vital for COTE1's functional activity, the inhibition by everolimus leads to a decrease in COTE1 activity. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 is a dual TORC1/TORC2 inhibitor, which affects the mTOR complex involved in the PI3K/AKT pathway. By inhibiting these complexes, Palomid 529 leads to reduced COTE1 activity, as COTE1's involvement in cellular growth and survival is contingent upon mTOR signaling. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent and selective ATP-competitive inhibitor of mTOR kinase, impacting both mTORC1 and mTORC2 complexes. This leads to diminished COTE1 activity by inhibiting the signaling required for its function. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an mTOR inhibitor that works across both mTORC1 and mTORC2 complexes. By inhibiting these complexes, COTE1's activity is diminished due to the reliance of its functional pathways on proper mTOR signaling. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU 0063794 is an advanced molecule that inhibits both mTORC1 and mTORC2, thereby reducing the activity of downstream proteins such as COTE1 that are dependent on mTOR's kinase activity. | ||||||